{
  "docId": "019de077-58c2-77ec-8b05-6d27c4bb0498",
  "docSlug": "35a6e53e15f172ec3a7e4b1f473eaa42",
  "documentTitle": "Genprex | Investor Presentation Deck | 58 slides",
  "authorId": "genprex",
  "authorName": "Genprex",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 58,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide includes a timeline of the study and two line charts showing tumor volume over time for different treatment groups.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-58c2-77ec-8b05-6d27c4bb0498/19",
  "deckHref": "/decks/019de077-58c2-77ec-8b05-6d27c4bb0498",
  "deckJsonHref": "/decks/019de077-58c2-77ec-8b05-6d27c4bb0498.json",
  "deckAnchorHref": "/decks/019de077-58c2-77ec-8b05-6d27c4bb0498#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.55,
        "x": 0.4,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Tumor volume over time for H1975-OsiR and H1975 tumors",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04cf1f69-2cdd-4dba-8a62-efcd8ca4654b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "paragraph",
      "text": "Enhanced Anti-Tumor Activity. REQORSA in combination with Tagrisso demonstrated significantly increased anti-tumor efficacy in EGFR mutant Tagrisso resistant NSCLC tumors in H1975-OsiR mouse xenografts.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae48c617-166a-4dfa-a078-7786796cade9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.55,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "TUSC2 = Reqorsa; Osimertinib is the generic name for Tagrisso.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f6bc68f2-1b08-411c-a45b-b762cbe2c083",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "AACR 21: Reqorsa® + Tagrisso Reduce Tumor Growth in Tagrisso Resistant Tumors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c5f58fc-7e4b-44ab-9516-cd519745c536",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 10,
      "beatId": "42876aa5-a597-4386-a7a4-77eba640e28a",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "Solution overview and clinical trial results",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 18,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6f78c908-9d3e-4d22-b345-671df04f3614",
      "evidence": "Discussion of drug resistance and limited treatment options",
      "position": 0,
      "objective": "Highlight the consequences of not adopting Genprex's gene therapies",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}